Summary of trials of adjuvant treatments for triple-negative breast cancer
| Adjuvant strategy | Study | Phase | Treatment | Primary endpoint |
|---|---|---|---|---|
| Anthracycline/taxane-based regimens | USO 97358,9 | III | AC*4 vs. TC*4 | Disease-free survival |
| ABC trial (USOR 06-090, NSABP B-46-I/OSOR 07132, and NSABP B-49)10 | III | TC*6 vs. TaxAC | Invasive disease-free survival | |
| WGS Plan B11 | III | EC*4-T*4 vs. TC*6 | Disease-free survival | |
| GEICAM 990612 | III | FEC*4-wP*8 vs. FEC*6 | Disease-free survival | |
| ECOG 119913 | III | AC*4-wP or wT or P every 3 weeks or T every 3 weeks | Disease-free survival | |
| Capecitabine regimens | CALGB 4990714 | III | Standard chemotherapy (CMF*6 or AC*4) vs. capecitabine | Relapse-free survival |
| FinXX15 | III | T*3-CEF*3 vs. TX*3-CEX*3 | Relapse-free survival | |
| CBCSG-01016 | III | T*3-CEF*3 vs. TX*3-CEX*3 | Disease-free survival | |
| SYSUCC-00117 | III | Standard treatment-X maintenance vs. standard treatment | Disease-free survival | |
| Platinum regimens | PATTERN18 | III | PCb*6 vs. CEF*3-T*3 | Disease-free survival |
A, doxorubicin; T, docetaxel; C, cyclophosphamide; TaxAC, one of several triple drug regimens that consist of cyclophosphamide, doxorubicin, and a taxane; E, epirubicin; F, fluorouracil; P, paclitaxel; wP, weekly paclitaxel; wT, weekly docetaxel; M, methotrexate; X, capecitabine; Cb, carboplatin.